Stock Events

Royalty Pharma 

$28.79
260
+$0.11+0.38% Friday 20:00

Statistics

Day High
29.07
Day Low
28.69
52W High
31.19
52W Low
24.8
Volume
2,495,068
Avg. Volume
2,412,639
Mkt Cap
12.98B
P/E Ratio
21.65
Dividend Yield
2.92%
Dividend
0.84

Upcoming

Dividends

2.92%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
7.3%
1Y Growth
5%

Earnings

9MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
0.72
1.01
1.31
1.6
Expected EPS
0.99
Actual EPS
0.98

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RPRX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
Bristol Myers Squibb is a global biopharmaceutical company that competes with Royalty Pharma in the acquisition and management of pharmaceutical royalties, particularly through its string of acquisitions that expand its portfolio in similar therapeutic areas.
Pfizer
PFE
Mkt Cap169.83B
Pfizer is a large pharmaceutical company that competes with Royalty Pharma in the development and commercialization of medical treatments, and it also engages in deals and partnerships that involve royalty agreements.
Gilead Sciences
GILD
Mkt Cap90.4B
Gilead Sciences is involved in the research, development, and commercialization of drugs in areas like HIV/AIDS, liver diseases, and oncology, competing with Royalty Pharma in acquiring royalties in these therapeutic areas.
Abbvie
ABBV
Mkt Cap304.29B
AbbVie operates in the pharmaceutical industry, focusing on acquiring and developing a portfolio of medicines, directly competing with Royalty Pharma in the market for drug royalties and investments in pharmaceutical innovations.
Merck &
MRK
Mkt Cap318.55B
Merck & Co. is a global healthcare company that competes with Royalty Pharma through its extensive drug development programs and partnerships that may involve royalty financing and agreements.
Johnson & Johnson
JNJ
Mkt Cap372.29B
Johnson & Johnson is a diversified healthcare giant that competes across various segments, including pharmaceuticals. Its involvement in drug development and royalty agreements places it in competition with Royalty Pharma.
Astrazeneca
AZN
Mkt Cap244.04B
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company, competing with Royalty Pharma in the acquisition of drug royalties and through its focus on innovative drug development.
Sanofi
SNY
Mkt Cap128.21B
Sanofi is a global healthcare leader that competes with Royalty Pharma in the pharmaceutical sector, particularly through its efforts to secure drug royalties and its focus on innovative treatments.
Novartis
NVS
Mkt Cap232.42B
Novartis is a global healthcare company that competes with Royalty Pharma through its significant investments in drug development and its strategy to acquire and manage drug royalties.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap19.04B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing with Royalty Pharma in the market for pharmaceutical royalties, especially in the generic sector where royalties are a key component of profitability.

Analyst Ratings

41.8$Average Price Target
The highest estimate is $51.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

About

Health Technology
Pharmaceuticals: Major
Manufacturing
Medicinal and Botanical Manufacturing
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Show more...
CEO
Pablo Gerardo Legorreta
Employees
75
Country
GB
ISIN
GB00BMVP7Y09
WKN
000A2P62D

Listings